ruthenium has been researched along with Adverse Drug Event in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrion, C; Gallardo-Villagrán, M; Léger, DY; Liagre, B; Martin, F; Ouk, C; Paulus, L; Therrien, B | 1 |
| Djinović, V; Grgurić-Sipka, S; Miljković, D; Momcilović, M; Mostarica Stojković, M; Sabo, T; Trajković, V | 1 |
2 other study(ies) available for ruthenium and Adverse Drug Event
| Article | Year |
|---|---|
The Effect of Photosensitizer Metalation Incorporated into Arene-Ruthenium Assemblies on Prostate Cancer.
Topics: Animals; Apoptosis; Drug-Related Side Effects and Adverse Reactions; Gastropoda; Humans; Male; Neoplasms, Second Primary; Photosensitizing Agents; Prostatic Neoplasms; Ruthenium | 2023 |
Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes.
Topics: Animals; Antineoplastic Agents; Astrocytes; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Growth Inhibitors; Ligands; Nitric Oxide; Nitrites; Organometallic Compounds; Platinum; Rats; Ruthenium; Spectrophotometry; Spectrophotometry, Infrared; Time Factors; Tumor Cells, Cultured | 2004 |